| |
Article Title |
Author(s) |
Pages |
|
|
|
Cover
|
|
OFC
|
|
|
|
Masthead
|
|
IFC
|
|
|
|
Eosinophilia: Introduction
Since the first descriptions of “unexplained eosinophilia” in the early 1900s, the etiology and pathogenesis of eosinophilia in human disease has provoked controversy. This stems, in part, from the fa...
|
Amy D. Klion
|
111-112
|
|
|
|
Eosinophils and Disease Pathogenesis
Eosinophils are granulocytic innate immune cells whose presence is conspicuous in a variety of disease states, including eosinophilic hyperproliferative and infiltrative processes, as well as conditio...
|
Praveen Akuthota,
Peter F. Weller
|
113-119
|
|
|
|
Eosinophilic Myeloid Disorders
The discovery of therapeutically relevant mutations involving platelet-derived growth factor receptors alpha and beta (PDGFRA and PDGFRB) changed the way we evaluate and treat patients with clonal eos...
|
Pierre Noel
|
120-127
|
|
|
|
Mast Cells and Eosinophils in Mastocytosis, Chronic Eosinophilic Leukemia, and Non-clonal Disorders
Mast cells and eosinophils often travel in the same biologic circles. In non-clonal states, such as allergic and inflammatory conditions, cell-to-cell contact and the pleiotropic actions of multiple c...
|
Jason Gotlib,
Cem Akin
|
128-137
|
|
|
|
Lymphoproliferative Disorders Associated With Hypereosinophilia
Hypereosinophilia, defined as peripheral blood eosinophil counts >1,500/μL, may complicate the course of various lymphoproliferative disorders. Among these, Hodgkin lymphoma (HL) and certain periph...
|
Florence Roufosse,
Soizic Garaud,
Laurence de Leval
|
138-148
|
|
|
|
Evaluation and Differential Diagnosis of Marked, Persistent Eosinophilia
High-grade eosinophilia can be a diagnostic dilemma, as the etiologies are extensive and varied. Hypereosinophilic syndromes (HES) are a group of heterogeneous disorders, many of which remain poorly d...
|
Rojelio Mejia,
Thomas B. Nutman
|
149-159
|
|
|
|
Therapeutic Approaches to Patients With Hypereosinophilic Syndromes
Hypereosinophilic syndromes (HES) are a heterogeneous group of disorders that range from asymptomatic eosinophilia >1,500/mL to aggressive disease complicated by life-threatening end organ involvem...
|
Hans-Uwe Simon,
Amy Klion
|
160-170
|
|
|
|
Controversies and Open Questions in the Definitions and Classification of the Hypereosinophilic Syndromes and Eosinophilic Leukemias
Eosinophilia is frequently detectable in certain myeloid neoplasms and various reactive conditions, but it may also occur in the absence of an apparent underlying disease, or, rarely, as a paraneoplas...
|
Peter Valent,
Hans-Peter Horny,
Bruce S. Bochner,
Torsten Haferlach,
Andreas Reiter
et al.
|
171-181
|
|
|
|
Treatment of Hypereosinophilic Syndromes—The First 100 Years
Treatment of the hypereosinophilic syndrome (HES) has advanced rapidly and prevention of end organ damage previously associated with the disorders is now possible in most patients who have had a timel...
|
J.H. Butterfield,
C.R. Weiler
|
182-191
|
|
|
|
Future Issues and Recent Issues
|
|
192
|
|
| Frontmatter |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Table of Contents
|
|
A1
|
|
|
|
Previous Issues
|
|
A2
|
|
